What is AptarGroup's pharma — D&A?

AptarGroup (ATR) reported pharma — D&A of $35.64M in Q1 2026.

How has AptarGroup's pharma — D&A changed year-over-year?

AptarGroup's pharma — D&A increased by 14.4% year-over-year, from $31.15M to $35.64M.

What does pharma — D&A mean?

The non-cash expense representing the systematic allocation of the cost of tangible and intangible assets over their useful lives. This reflects the ongoing consumption of the segment's capital base.

AptarGroup ATR Pharma — D&A

Other segment segments

Beauty

$24.72M+23.2%

Closures

$14.22M+4.8%

Similar metrics at other companies

PFEBiopharma — D&A

$348M+5.1%

CAHPharmaceutical and Specialty Solutions — D&A

$70M+59.1%

BDXBioPharma Systems — D&A

$27M-15.6%

CORTD&A

$598K+29.4%

BMYD&A

$594M-41.3%

NBIXD&A

$7.2M+9.1%

Other financials

Income statement

See full

Revenue$982.9M+10.8%

Gross profit$351.9M+4.6%

Operating income$107.5M-5.2%

Net income$72.7M-7.8%

EPS (diluted)$1.12-4.3%

Balance sheet

See full

Cash & equivalents$225.0M+78.8%

Total debt$1.4B+32.7%

Total equity$2.6B+3.6%

Total assets$5.1B+12.6%

Cash flow

See full

Operating cash flow$118.7M+43.5%

CapEx$65.4M+15.0%

Free cash flow$53.3M+106%

Valuation

See full

Market cap$7.68B-17.9%

Enterprise value$8.89B-13.9%

P/E19.9×-5.4×

P/S2×-0.6×

Profitability

See full

Gross margin36.7%-1.6pp

Operating margin12.8%-1.2pp

Net margin10%-0.4pp

FCF margin8.4%-2.1pp

Returns & leverage

See full

Return on equity15%-0.2pp

Debt / equity0.5×+0.1×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: AptarGroup’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's pharma — d&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AptarGroup's pharma — D&A?: AptarGroup (ATR) reported pharma — D&A of $35.64M in Q1 2026.
How has AptarGroup's pharma — D&A changed year-over-year?: AptarGroup's pharma — D&A increased by 14.4% year-over-year, from $31.15M to $35.64M.
What does pharma — D&A mean?: The non-cash expense representing the systematic allocation of the cost of tangible and intangible assets over their useful lives. This reflects the ongoing consumption of the segment's capital base.